CRISPR відкриті
[search 0]
більше
Download the App!
show episodes
 
CRISPR is a new technology able to edit the genes of plants to make them stronger, healthier, and more abundant. In a world facing global warming and climate change, unconventional science may be our only hope. Cover art photo provided by Johannes Plenio on Unsplash: https://unsplash.com/@jplenio
  continue reading
 
Artwork

1
CRISPR Unedited

Bitesize Bio

Unsubscribe
Unsubscribe
Щомісяця
 
Hosted by Dr Antony Adamson (The University of Manchester), the 'CRISPR unedited' podcast brings together researchers from around the world to share their practical knowledge on CRISPR to help you get the most out of your research. This set of engaging, fun, and energetic conversations serves to highlight the latest and upcoming CRISPR technologies, and provide helpful advice no matter where you are in your CRISPR journey.
  continue reading
 
Hosted by Kevin Davies, PhD, GuidePost is an exciting podcast series featuring candid conversation with the pioneers and practitioners of CRISPR and gene editing research. Guests have included luminaries Emmanuelle Charpentier, Francisco Mojica, Rodolphe Barrangou, Virginijus Siksnys, Sylvain Moineau, and Jakob Sherkow, among others. GuidePost is produced by The CRISPR Journal, the only peer-reviewed journal dedicated to the science and applications of gene editing.
  continue reading
 
Loading …
show series
 
Imran House, Ph.D. and Junyun Lai Ph.D. are Senior Scientists at the biotech start-up, oNKo-Innate in Melbourne, Australia that focuses on developing immuno-oncology therapies. In this episode, they discussed what they do at oNKo-innate, their career transitions from leaving academics to entering the biotech industry, and how CRISPR is impacting ca…
  continue reading
 
Dr. Mark DeWitt Ph.D., Associate Director at Mammoth Biosciences, and Dr. Don Kohn M.D., distinguished professor and Director of the UCLA Human Gene and Cell Therapy Program and CIRM grantee sat down with us to discuss their latest clinical trials to cure sickle cell anemia, how synthetic guides accelerated their journey from the bench to the clini…
  continue reading
 
Dina Simkin, Professor of Neurology at Northwestern University, joins us in this episode of CRISPR Cuts. Dr. Simkin talks about her path to becoming a researcher, art, and the importance of patient and isogenic iPSC models to study genetically linked forms of epilepsies.Synthego
  continue reading
 
#3 — In this episode of CRISPR Unedited, Antony Adamson is joined by Bernhard Schmierer, Researcher at the Karolinska Institutet who heads the CRISPR Functional Genomics Facility at SciLifeLab. They discuss the day-to-day practicalities of performing CRISPR screens, share the vast number of cells needed for screening and highlight key literature yo…
  continue reading
 
Dr. Sunil Sharma and Dr. Raffaella Soldi of the Translational Genomics Research Institute chat about using CRISPR arrayed screens to identify novel drug targets for Ewing's Sarcoma, outlooks for the future of cancer therapies, and the Arizona heat.Synthego
  continue reading
 
#2 — In this episode of CRISPR Unedited, Antony Adamson is joined by Pia Johansson, Scientific Coordinator at the Cell and Gene Therapy core at Lund University. Together they answer your practical questions about CRISPR gene editing, covering topics such as transfection, off-target effects, and the difference between CRISPRi and RNAi. The inspirati…
  continue reading
 
Professor Stephanie Cherqui, UCSD, has worked on the development of cell therapies for two rare genetic diseases, cystinosis and Friedreich’s ataxia. In this interview, Dr. Cherqui chats about her experience working on rare diseases, developing a CRISPR-edited therapy for Friedreich's ataxia, navigating regulatory challenges in cell and gene therap…
  continue reading
 
#1 — Matthew Cobb is Professor of Zoology at the University of Manchester. In this episode, Matthew joins our host Antony Adamson to chat about the exciting early days of genetic manipulation and some of the fears that prompted the scientists involved to build new safeguards and self-regulation. They discuss gene editing, the advent of CRISPR, and …
  continue reading
 
Hosted by Dr Antony Adamson (The University of Manchester), the 'CRISPR Unedited' podcast brings together researchers from around the world to share their practical knowledge on CRISPR to help you get the most out of your research. This set of engaging, fun, and energetic conversations serves to highlight the latest and upcoming CRISPR technologies…
  continue reading
 
Tune in to hear Christian Groendahl, CEO of SNIPR Biome, talk about CRISPR editing in prokaryotes, their novel E. coli-targeting CRISPR therapy trials, and his experiences and vision leading a start up.Synthego
  continue reading
 
In this episode, Bryan Dechairo, CEO of Sherlock Biosciences, talks about the impact of technology advances in the field of CRISPR diagnostics, his experiences leading Sherlock Biosciences, and his team’s mission of accessibility.Synthego
  continue reading
 
Dr. Ayal Hendel, a genome-editing pioneer and group leader at Bar Ilan University in Israel, was one of the first researchers to use modified synthetic sgRNA to edit primary cells with CRISPR. In this episode, Dr. Hendel shares his perspectives on the recent CRISPR advancements and his work on the bubble boy disease.…
  continue reading
 
Jimi has dealt with sickle cell disease, a genetic disorder with serious implications, his entire life. Undergoing a CRISPR gene editing trial turned his hope for a cure into reality with promising results from the early phases. Tune in to learn about Jimi's journey in this episode.Synthego
  continue reading
 
After being diagnosed with aggressive prostate cancer, Bryce Olson quickly learned the science behind it and has leveraged NGS to understand his tumor genomics and find opportunities in personalized therapies. Hear the patient perspective for the first time on our podcast through Bryce's narration of his experience and pursuit of next generation ce…
  continue reading
 
In this collaboration episode with NEB, we interview Dr. Neville Sanjana, a core faculty member at the New York Genome Center, about his recent publication in which chemically modified guide RNAs were used to enhance CRISPR-Cas13 knockdown in human cells.Synthego
  continue reading
 
Anthropologist and author Eben Kirksey discusses his interest in somatic and hereditary human genome editing, particularly the impact on patients and practitioners, the history of CCR5 gene editing, and recalls his exceptional reporting in China in the wake of the CRISPR babies scandal, all of which is included in his riveting book “The Mutant Proj…
  continue reading
 
In this episode, we chat with Dr. Kiana Aran, the CSO of Cardea Bio and associate professor at Keck Graduate Institute, who recently won the Nature Research Award for Inspiring Women in Science. Dr. Aran talks about her experience being a nominee and award winner, her early days and scientific journey, and the launch of her new non-profit, Aran Neb…
  continue reading
 
We chatted with six female leaders in the CRISPR—Alison van Eenennaam, Ph.D., Kiana Aran, Christina Trojel-Hansen, Ph.D., Laura Lambert, Ph.D., Elena Miñones Moyano, Ph.D., and Samantha Maragh, Ph.D.— about their professional journeys. Tune in to this episode for a candid and honest discussion on a broad range of topics, including their experiences…
  continue reading
 
In this CRISPR Cuts episode, Dr. Jesse Boehm, the Chief Scientific Officer of the Break Through Cancer Foundation and principal investigator at the Broad Institute, talks about his work on rare cancers. He also covers how CRISPR technology is transforming cancer research.Synthego
  continue reading
 
The Inducible Pluripotent Stem Cell Neurodegeneration Initiative (iNDI), an NIH effort, aims to standardize disease models for Alzheimer’s and related dementias. Hear the principal contributors, Dr. Michael E. Ward and Dr. Mark R. Cookson, scientists at the NIH, talk about the inception of the iNDI project, the challenges and opportunities, and the…
  continue reading
 
Prime editing is a new genome engineering tool that emerged just a couple of years back. Right from the get-go, this technology made waves as a potential alternative to CRISPR. Now, the first comparative study in mice is out. Dr. Joe Miano, Professor at the Augusta University in Georgia, talks about their collaborative work comparing traditional CR…
  continue reading
 
Did you know cassava can cause cyanide poisoning if it is not processed correctly and consumed with a protein-poor diet? In this episode, we chat with IGI researchers, Jess Lyons and Michael Gomez about their work on using CRISPR to reduce cyanide in cassava and improve its food safety.Synthego
  continue reading
 
The architect of base editing and prime editing, Harvard University chemist David R. Liu, recalls the genesis of the technology and discusses exciting preclinical results and potential future applications.{Sponsored by Pegasus Books}The CRISPR Journal
  continue reading
 
In this podcast, Mendelspod host Theral Timpson interviews Kevin Davies about his latest book, "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing".{Episode Sponsored by Mendelspod}The CRISPR Journal
  continue reading
 
Kevin Davies, the executive editor of The CRISPR Journal, has closely watched the genetics space evolve over the last decades. His expertise and experience were the perfect foundation for his latest book "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing." In this episode, Kevin discusses his motivation for the book, along w…
  continue reading
 
In this episode, Michael Friend, CEO of Minority Coalition for Precision Medicine, discusses the lack of diversity in genome editing field and covers potential solutions for ensuring an inclusive future, particularly for black scientists.Synthego
  continue reading
 
A conversation with Dame Kay Davies, University of Oxford geneticist and co-chair of the just-published international commission report on Hereditary Human Genome Editing (HHGE), which lays out a roadmap for if, when, and how we should proceed with embryo editing for couples with severe genetic diseases.…
  continue reading
 
The COVID-19 pandemic is a unique situation for lab scientists, many of whose work has come to a standstill. Hamid Ghanadaan, CEO of Linus, discusses the impact of COVID-19 on science and the next steps for scientists, based on their survey of >1000 scientists.Synthego
  continue reading
 
The mission of Indee Labs, a Berkeley biotech, is to deliver CRISPR reagents into cells using microfluidics for developing affordable cell and gene therapies in the future. We interviewed Ryan Pawell, Founder and CEO of Indee Labs, about the concept of using microfluidics for CRISPR delivery, their mission and ongoing projects, and the convergence …
  continue reading
 
Shondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.Synthego
  continue reading
 
Canadian law professor Bartha Knoppers (McGill University) talks about her long-standing interests in genetics, bioethics, human rights and her latest role studying the clinical implementation of genome editing.The CRISPR Journal
  continue reading
 
Rebecca Shapiro, Assistant Professor at the University of Guelph, talks about CRISPR genome editing in fungal pathogens to understand their disease-causing mechanism. Her lab also works on gene drives in fungi for studying large scale genetic interactions and developing ways for treating fungal biofilms.…
  continue reading
 
The recently retired founding CEO of Sangamo Therapeutics, Edward Lanphier, shares stories from two decades at the helm of the first biotech company to develop and take genome editing, using zinc finger nucleases, into the clinic.The CRISPR Journal
  continue reading
 
In this interview, Paul Dabrowski, CEO of Synthego, talks about how Synthego got started, his mantra behind leading the company, and future directions. He also offers insights into Synthego’s unique capabilities⁠—the powerful combination of engineering and biology that enable scaling.Synthego
  continue reading
 
CRISPR has great potential in therapeutics, but CRISPR delivery in vivo remains a challenge. Researcher Dana Foss discusses her lab’s novel approach for specific delivery of CRISPR components in cells and tissues.Synthego
  continue reading
 
While postdocs in David Liu’s lab at Harvard University, Alexis Komor (UCSD) and Nicole Gaudelli (Beam Therapeutics) developed a pair of CRISPR-based molecular machines known as base editors, capable of engineering precise single-base substitutions with enormous basic research and therapeutic implications.…
  continue reading
 
Megan Hochstrasser, Science Communications Manager at the Innovative Genomics Institute, talks about the importance of CRISPR science communication and the ongoing efforts at IGI to help people understand this genome engineering tool.Synthego
  continue reading
 
Loading …

Короткий довідник